AbbVie’s stock reached a new high following a 33% gain this year and an earnings beat with adjusted EPS of $3.82, beating estimates. The company raised its full-year EPS guidance and quarterly dividend, driven by strong sales of Skyrizi and Rinvoq, which grew over 22%. Despite a high valuation with a GAAP P/E of 122, Wall Street remains mostly bullish, expecting further upside to around $315 if pipeline developments and new drug launches accelerate growth. Risks include declines in Humira sales and high valuation levels, but AbbVie is seen as a quality company trading near fair value with potential for moderate gains over the next few years.
AbbVie holds a substantial market cap of $510.41 billion and offers a dividend yield of 2.43% as of Nov 03, 2026 23:21 WIB on Pluang. Despite a slight 0.13% dip in price to $288.57, the stock sees active trading with a volume of 8,832,490 shares. The platform data shows a typical hold time of 93 days, indicating moderate investor confidence in the stock's medium-term prospects.
AbbVie Inc. reported strong Q3 results with revenue up 10.3% year-over-year to $17.4 billion, beating analyst expectations. Non-GAAP earnings per share more than doubled, rising 105.4%. The company's IL-23 antagonist drug Skyrizi saw sales grow 22.7%...
Nasdaq futures fell over 2% due to a sell-off in Big Tech stocks like Intel and Amazon, dragging the tech-heavy index down. Meanwhile, the Dow Jones Industrial Average remained flat, supported by strong earnings beats from companies like Chevron and ...
AbbVie reported a strong third quarter with adjusted diluted earnings per share (EPS) of $3.82, more than doubling from the previous year, driven by a 10.3% increase in net revenues to $17.4 billion. Key growth came from its immunology and neuroscien...
